Autism social cognition
Sikich 2021 (NEJM, n=290) randomized children and adolescents with ASD to intranasal oxytocin vs placebo for 24 weeks and found no significant difference on the primary social functioning endpoint. This large definitive trial reframed the smaller positive trials (Guastella 2010, Yatawara 2016) as likely false positives.
6 human studies · 12 animal studies
Key findings & citations
- Sikich 2021: no improvement in social withdrawal score vs placebo over 24 weeks.
- Earlier smaller trials reported acute emotion-recognition improvements.
- Replication of acute oxytocin effects has been inconsistent across labs.
Our take
The definitive RCT was negative. Don't expect oxytocin nasal spray to treat autism — that hypothesis didn't survive rigorous testing.